Fzata, Inc. is an award-winning biotechnology company based in Halethorpe, Maryland, specializing in the development of oral biologics for the treatment of gastrointestinal disorders. Their innovative platform, BioPYM, utilizes bioengineered probiotic yeast micro-factories to produce therapeutic biologics directly in the gut, offering improved safety, efficacy, and accessibility for patients.
With a focus on enhancing patient outcomes, Fzata's oral biologics target the site of disease in the gastrointestinal tract, eliminating the need for systemic administration and reducing the risk of toxicities. By providing at-home, non-refrigerated oral capsules, Fzata aims to improve patient compliance and convenience, offering an alternative to traditional injection-based therapies. With their high safety profile and absence of systemic toxicity, Fzata's BioPYM platform holds great promise for the future of biologic therapeutics.
Generated from the website